A nurse is preparing to administer digoxin 0.25 mg PO to a client. The amount available is digoxin 0.125 mg tablets. How many tablets should the nurse administer to the client?

(Round to the nearest whole number. Use a leading zero if it applies. Do not use a trailing zero.)

A. Food, Drug and Cosmetic Act (FD&C Act): This act sets the groundwork for food and drug regulations, but it's not the specific legislation governing dietary supplements. While FD&C Act applies to some aspects of supplements, DSHEA has more specific regulations.

B. Joint Commission on the Accreditation of Healthcare Organizations (JCAHO): This organization focuses on accrediting healthcare facilities, not regulating supplements.

C. Health and Human Services (HHS): HHS is a broad department encompassing various healthcare agencies, but DSHEA is the specific act within HHS that governs supplements.

D. Dietary Supplement Health and Education Act (DSHEA): This 1994 act specifically addresses dietary supplements, outlining regulations for labeling, manufacturing, and marketing. It places the responsibility for ensuring the safety and effectiveness of supplements on the manufacturers, unlike prescription drugs approved by the FDA.

A. If he misses a dose, he should double the dose at the next scheduled time: This statement is incorrect. Doubling the dose of warfarin after missing a dose can significantly increase the risk of bleeding due to excessive anticoagulation. The nurse should emphasize the importance of taking the medication as prescribed and what to do if a dose is missed, such as contacting the healthcare provider for guidance.

B. The client should use an electric razor while on this medication: This statement is correct. Warfarin is an anticoagulant medication that can increase the risk of bleeding. Therefore, it's essential for patients taking warfarin to avoid activities that may increase the risk of injury or bleeding, such as shaving with a traditional razor that can cause cuts or nicks. Using an electric razor reduces this risk.

C. Mild nosebleeds are common during initial treatment: This statement is not entirely accurate. While warfarin can increase the risk of bleeding, including nosebleeds, it's not necessarily common during the initial treatment phase. However, patients should be aware of signs of bleeding and report them to their healthcare provider promptly.

D. Warfarin increases the risk for deep vein thrombosis: This statement is incorrect. Warfarin is actually prescribed to reduce the risk of blood clots, including deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke, in patients who are at risk for these conditions. It works by inhibiting the formation of blood clots. Therefore, it does not increase the risk of DVT; rather, it decreases it.